A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Recruiting · NCT06942572 · Registry updated 2025-04-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Stargardt disease, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 1 / Phase 2 | 2025-04-29 | NCT06942572 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Splice Bio | 2 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Bascom Palmer Eye Institute | Miami | United States | 17 |
| Massachusetts Eye and Ear Infirmary | Boston | United States | 18 |
| Oregon Health & Science University | Portland | United States | 261 |
| Retina Foundation of the Southwest | Dallas | United States | 1 |
| UCHealth Sue Anschutz-Rodgers Eye Center, | Aurora | United States | 1 |